Document Detail

Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
MedLine Citation:
PMID:  20206069     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. METHODS AND RESULTS: Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n=15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n=15), or hydration alone (control group, n=15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 + or - 0.36 to 0.67 + or - 0.16 mg/dl (p<0.01), and Ccr significantly increased from 62.4 + or - 15.6 to 80.4 + or - 8.39 ml/min (p<0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 + or - 0.21 to 1.28 + or - 0.21 mg/dl (p<0.01), and Ccr significantly decreased from 63.7 + or - 16.1 to 46.1 + or - 10.6 ml/min (p<0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 + or - 0.58 to 1.71 + or - 0.38 mg/dl (p<0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 + or - 31.0 to 239 + or - 34 microg/ml (p<0.01). CONCLUSIONS: These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.
Terufumi Kinbara; Tomoko Hayano; Nozomu Ohtani; Yuhji Furutani; Kohshiro Moritani; Masunori Matsuzaki
Related Documents :
22981019 - Short-term outcomes of the c3 excluder for patients with abdominal aortic aneurysms and...
17254739 - Carbon dioxide digital subtraction angiography-assisted endovascular aortic aneurysm re...
24993649 - How often is functional range of motion obtained by manipulation for stiff total knee a...
6440419 - Kidney function and quantitative histological changes in patients on long-term lithium ...
23652169 - Effects of intraoperative colloid administration on outcome in a population-based gener...
24488849 - Lumbo-sacral motion conserved after isthmic reconstruction: long-term results.
17445639 - Comparative evaluation of efficacy of use of tamsulosin and/or tolterodine for medical ...
23379449 - Introduction of an n-acetylcysteine weight-based dosing chart reduces prescription erro...
22473139 - The efficacy of schroth`s 3-dimensional exercise therapy in the treatment of adolescent...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-12-01
Journal Detail:
Title:  Journal of cardiology     Volume:  55     ISSN:  0914-5087     ISO Abbreviation:  J Cardiol     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-08     Completed Date:  2010-08-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804703     Medline TA:  J Cardiol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  174-9     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Department of Cardiology, National Hospital Organization, Kanmon Medical Center, 1-1 Chofusotoura-cho, Shimonoseki, Yamaguchi 752-8510, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylcysteine / administration & dosage,  therapeutic use*
Aminophylline / administration & dosage,  therapeutic use*
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects*
Contrast Media / adverse effects*
Coronary Angiography / adverse effects*
Creatinine / blood,  metabolism
Kidney Diseases / chemically induced*,  prevention & control*
beta 2-Microglobulin / blood,  urine
Reg. No./Substance:
0/Contrast Media; 0/beta 2-Microglobulin; 317-34-0/Aminophylline; 60-27-5/Creatinine; 616-91-1/Acetylcysteine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Generator-produced rubidium-82 positron emission tomography myocardial perfusion imaging-From basic ...
Next Document:  Treatment of non-left main bifurcation lesions using the sirolimus-eluting stent: A comparison of ch...